Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven H J Hageman

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Journal of Evaluation in Clinical Practice|January 13, 2025
Low Attainment of Treatment Targets for Cardiovascular Risk Factors in Indonesian Adults With Established Coronary Artery DiseaseDian Sidik Arsyad, Nurul Qalby, Andriany Qanitha, et al.
Open Heart|February 16, 2026
External validation of the SMART2 model for recurrent cardiovascular risk: performance in socioeconomic, ethnic and psychiatric subgroupsJasper Wilhelmus Adrianus van Egeraat, Nan van Geloven, Steven H J Hageman, et al.
European Journal of Preventive Cardiology|June 28, 2025
External validation of the Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in cancer patientsMari Nordbø Gynnild, Joris Holtrop, Steven H J Hageman, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 20, 2023
Variability in benefit from intensive insulin therapy on cardiovascular events in individuals with type 1 diabetes: A post hoc analysis of the DCCT/EDIC studyMarga A G Helmink, Steven H J Hageman, Frank L J Visseren, et al.
European Heart Journal|September 1, 2024
Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model, Steven H J Hageman, Zijuan Huang, et al.
European Journal of Preventive Cardiology|August 26, 2025
Psychological factors beyond the SMART2 model for predicting recurrent events in atherosclerotic cardiovascular disease patientsJoris Holtrop, Mari Nordbø Gynnild, Toril Dammen, et al.
Endocrine Connections|March 9, 2026
Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UKThomas van Sloten, Steven H J Hageman, Jan Westerink, et al.
Stroke|September 25, 2024
Prediction of Severe Baseline Asymptomatic Carotid Stenosis and Subsequent Risk of Stroke and Cardiovascular DiseaseMichiel H F Poorthuis, Steven H J Hageman, Aernoud T L Fiolet, et al.
European Journal of Preventive Cardiology|October 4, 2023
Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohortTinka J van Trier, Marjolein Snaterse, S Matthijs Boekholdt, et al.
American Heart Journal Plus : Cardiology Research and Practice|July 29, 2025
Clinical benefit and cost effectiveness of adding life-time low-dose colchicine as secondary prevention following coronary artery bypass grafting surgerySai Rahul Ponnana, Gauranga Mahalwar, Joris Holtrop, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Journal of Evaluation in Clinical Practice|January 13, 2025
Low Attainment of Treatment Targets for Cardiovascular Risk Factors in Indonesian Adults With Established Coronary Artery DiseaseDian Sidik Arsyad, Nurul Qalby, Andriany Qanitha, et al.
Open Heart|February 16, 2026
External validation of the SMART2 model for recurrent cardiovascular risk: performance in socioeconomic, ethnic and psychiatric subgroupsJasper Wilhelmus Adrianus van Egeraat, Nan van Geloven, Steven H J Hageman, et al.
European Journal of Preventive Cardiology|June 28, 2025
External validation of the Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in cancer patientsMari Nordbø Gynnild, Joris Holtrop, Steven H J Hageman, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 20, 2023
Variability in benefit from intensive insulin therapy on cardiovascular events in individuals with type 1 diabetes: A post hoc analysis of the DCCT/EDIC studyMarga A G Helmink, Steven H J Hageman, Frank L J Visseren, et al.
European Heart Journal|September 1, 2024
Risk prediction of cardiovascular disease in the Asia-Pacific region: the SCORE2 Asia-Pacific model, Steven H J Hageman, Zijuan Huang, et al.
European Journal of Preventive Cardiology|August 26, 2025
Psychological factors beyond the SMART2 model for predicting recurrent events in atherosclerotic cardiovascular disease patientsJoris Holtrop, Mari Nordbø Gynnild, Toril Dammen, et al.
Endocrine Connections|March 9, 2026
Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UKThomas van Sloten, Steven H J Hageman, Jan Westerink, et al.
Stroke|September 25, 2024
Prediction of Severe Baseline Asymptomatic Carotid Stenosis and Subsequent Risk of Stroke and Cardiovascular DiseaseMichiel H F Poorthuis, Steven H J Hageman, Aernoud T L Fiolet, et al.
European Journal of Preventive Cardiology|October 4, 2023
Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohortTinka J van Trier, Marjolein Snaterse, S Matthijs Boekholdt, et al.
American Heart Journal Plus : Cardiology Research and Practice|July 29, 2025
Clinical benefit and cost effectiveness of adding life-time low-dose colchicine as secondary prevention following coronary artery bypass grafting surgerySai Rahul Ponnana, Gauranga Mahalwar, Joris Holtrop, et al.
Pageof 4